First International Symposium on Influenza and Other Respiratory Viruses: Summary and overview: Kapalua, Maui, Hawaii, December 4-6, 1998

Antiviral Research

Volumn 42, Issue 3, 1999, Pages

  Kaiser, Laurent ^a   Couch, Robert B ^b   Galasso, George J ^b   Glezen, W Paul ^b   Webster, Robert G ^b   Wright, Peter F ^b   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

Epidemiology; Influenza; Respiratory viruses; Vaccines

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RUPINTRIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

CONFERENCE PAPER; INFLUENZA; INFLUENZA VIRUS; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHINOVIRUS; VACCINATION; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; HAWAII; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 0345535832     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00034-0     Document Type: Conference Paper

References (94)

1. Prevention and control of influenza. Morbidity Mortality Weekly Rep. 46:1997;1-25.
2. Aoki F.Y., Osterhaus A.D., Rimmelzwaan G.F., Kinnersley N., Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998;American Society of Microbiology, San Diego. Abstract #LB5.
3. Arnold R., Humbert B., Werchau H., Gallati H., Konig W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology. 82:1994;126-133.
4. Arruda E., Hayden F.G., McAuliffe J.F., de S.M.A., Mota S.B., McAuliffe M.I., Geist F.C., Carvalho E.P., Fernandes M.C., Guerrant R.L., Gwaltney J.M. Acute respiratory viral infections in ambulatory children of urban northeast Brazil. J. Infect. Dis. 164:1991;252-258.
5. Bates P.J., Bardin P.G., Fraenkel D.J., Sanderson G., Holgate S.T., Johnston S.L. Localisation of rhinovirus in the bronchial epithelium of experimentally infected human volunteers. Am. J. Respir. Crit. Care Med. 157(3):1998;. Abstract 25.
6. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.I., Hayden F.G., Kotloff K., Zangwill K., Iacuzio D., Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338:1998;1405-1412.
7. Calfee D.P., Hayden F.G. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs. 56(4):1998;537-553.
8. Calfee D.P., Peng A.W., Cass L., Lobo M., Hayden F.G. Protective efficacy of intravenous zanamivir in experimental human influenza. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998;American Society of Microbiology, San Diego. Abstract #H-58.
9. Cherian T., Simoes E.A., Steinhoff M.C., Chitra K., John M., Raghupathy P., John T.J. Bronchiolitis in tropical south India. Am. J. Dis. Child. 144:1990;1026-1030.
10. Chew F.T., Doraisingham S., Ling A.E., Kumarasinghe G., Lee B.W. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol. Infect. 121:1998;121-128.
11. Collinson J., Nicholson K.G., Cancio E., Ashman J., Ireland D.C., Hammersley V., Kent J., O'Callaghan C. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax. 51:1996;1115-1122.
12. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 129:1974;411-420.
13. Couch R.B., Kasel J.A., Six H.R., Cate T.R., Zahradnik J.M. Immunological reactions and resistance to infection with influenza virus. Stuart-Harris C., Potter C. Molecular Virology and Epidemiology of Influenza. Beecham Symposium, London 1983. 1984;119-153 Academic Press, London.
14. Delage G., Brochu P., Robillard L., Jasmin G., Joncas J.H., Lapointe N. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. Arch. Pathol. Lab. Med. 108:1984;623-625.
15. Di F.S., Mbawuike I.N., Kiyono H., Fujihashi K., Couch R.B., McGhee J.R. Quantitation of human influenza virus-specific cytotoxic T lymphocytes, correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Int. Immunol. 6:1994;11-19.
16. Dowdle W.R., Downie J.C., Laver W.G. Inhibition of virus release by antibodies by surface antigens of influenza virus. J. Virol. 13:1974;269-275.
17. Drinka P.J., Gravenstein S., Schilling M., Krause P., Miller B.A., Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A - a comparison of two protocols. Arch. Int. Med. 158:1998;2155-2159.
18. Efthymiopoulos C., Barrington P., Patel J.A. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal, and inhaled administration in man. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994;American Society of Microbiology, New Orleans. Abstract #H70.
19. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., Doherty P.C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174:1991;875-880.
20. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., Weiner L.B., Bonville C.A., Betts R.F. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
21. Fan J., Henrickson K.J., Savatski L.L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin. Infect. Dis. 26:1998;1397-1402.
22. Folkerts G., Busse W.W., Nijkamp F.P., Sorkness R., Gern J.E. Virus-induced airway hyperresponsiveness and asthma. Am. J. Respir. Crit. Care Med. 157:1998;1708-1720. (review).
23. Fraenkel D.J., Bardin P.G., Sanderson G., Lampe F., Johnston S.L., Holgate S.T. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am. J. Respir. Crit. Care Med. 151:1995;879-886.
24. Gern J.E., Calhoun W., Swenson C., Shen G., Busse W.W. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am. J. Respir. Crit. Care Med. 155:1997;1872-1876.
25. Gern J.E., Galagan D.M., Jarjour N.N., Dick E.C., Busse W.W. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am. J. Respir. Crit. Care. Med. 155:1997;1159-1161.
26. Graham B.S., Davis T.H., Tang Y.W., Gruber W.C. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr. Res. 34:1993;167-172.
27. Grunberg K., Timmers M.C., Smits H.H., de Klerk E.P., Dick E.C., Spaan W.J., Hiemstra P.S., Sterk P.J. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin. Exp. Allergy. 27:1997;36-45.
28. Grunberg K., Smits H.H., Timmers M.C., de Klerk E.P., Dolhain R.J., Dick E.C., Hiemstra P.S., Sterk P.J. Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am. J. Respir. Crit. Care Med. 156:1997;609-616.
29. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262.
30. Gwaltney J.M. Jr., Phillips C.D., Miller R.D., Riker D.K. Computed tomographic study of the common cold. N. Engl. J. Med. 330:1994;25-30.
31. Han L.L., Alexander J.P., Anderson L.J. Respiratory syncytial virus pneumonia among elderly. An assessment of disease burden. J. Infect. Dis. 1:1999;25-30.
32. Hayden F.G., Gwaltney J.M.J. Viral infections. Murray J.F., Nadel J.D. Textbook of Respiratory Medicine. 1994;977-1035 Saunders, Philadelphia.
33. Hayden F.G., Rollins B.S., Madren L.K. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 25:1994;123-131. (published erratum appears in Antiviral Res. 25(3-4), 287, 1994).
34. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 275:1996;295-299.
35. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337:1997;874-879.
36. Hayden F.G., Lobo M., Treanor J.J., Miller M., Mills R.G. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997;American Society for Microbiology, Toronto. Abstract #LB-26.
37. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz A., Parr D., Huson L., Ward P., Mills R.G. Safety and efficacy of oral GS4104 in long-term prophylaxis of natural influenza. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998;American Society of Microbiology, San Diego. Abstract #LB6.
38. Hazlett D.T., Bell T.M., Tukei P.M., Ademba G.R., Ochieng W.O., Magana J.M., Gathara G.W., Wafula E.M., Pamba A., Ndinya-Achola J.O. Viral etiology and epidemiology of acute respiratory infections in children in Nairobi, Kenya. Am. J. Trop. Med. Hyg. 39:1988;632-640.
39. Hemming V.G., Rodriguez W., Kim H.W., Brandt C.D., Parrott R.H., Burch B., Prince G.A., Baron P.A., Fink R.J., Reaman G. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31:1987;1882-1886.
40. Hemming V.G., Prince G.A., Groothuis J.R., Siber G.R. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:1995;22-33. (review).
41. Henderson F.W., Collier A.M., Clyde W.A. Jr., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300:1979;530-534.
42. Jackson M., Scott R. Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. J. Med. Virol. 49:1996;161-169.
43. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72:1998;2871-2880.
44. Johnston S.L., Pattemore P.K., Sanderson G., Smith S., Lampe F., Josephs L., Symington P., O'Toole S., Myint S.H., Tyrrell D.A. Community study of role of viral infections in exacerbations of asthma in 9-11-year-old children. Br. Med. J. 310:1995;1225-1229.
45. Johnston S.L., Pattemore P.K., Sanderson G., Smith S., Campbell M.J., Josephs L.K., Cunningham A., Robinson B.S., Myint S.H., Ward M.E., Tyrrell D.A., Holgate S.T. The relationship between upper respiratory infections and hospital admissions for asthma, a time-trend analysis. Am. J. Respir. Crit. Care Med. 154:1996;654-660.
46. Johnston S.L. Bronchial hyperresponsiveness and cytokines in virus-induced asthma exacerbations. Clin. Exp. Allergy. 27:1997;7-9. (editorial comment).
47. Joshi S.B., Dutch R.E., Lamb R.A. A core trimer of the paramyxovirus fusion protein, parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology. 248:1998;20-34.
48. Kelso A., Baumgarth N., Groves P. Cytokine-producing T cells in influenza virus infection. Brown L.E., Hampson A.W., Webster R.G. Options for the Control of Influenza III. 1996;170-179.
49. Konig B., Krusat T., Streckert H.J., Konig W. IL-8 release from human neutrophils by the respiratory syncytial virus is independent of viral replication. J. Leukocyte Biol. 60:1996;253-260.
50. Lambert D.M., Barney S., Lambert A.L., Guthrie K., Medinas R., Davis D.E., Bucy T., Erickson J., Merutka G., Petteway S.R. Jr. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. USA. 93:1996;2186-2191.
51. Mbawuike I.N., Acuna C.L., Walz K.C., Atmar R.L., Greenberg S.B., Couch R.B. Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12. Mech. Ageing Dev. 94:1997;25-39.
52. McMichael A.J., O'Callaghan C.A. A new look at T cells. J. Exp. Med. 187:1998;1367-1371.
53. Monto A.S., Ohmit S.E., Hornbuckle K., Pearce C.L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob. Agents Chemother. 39:1995;2224-2228.
54. Monto A.S., Robinson D.P., Herlocher L., Hinson J.M., Elliott M., Keene O. Efficacy and safety of zanamivir in prevention of influenza among healthy adults. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998;American Society of Microbiology, San Diego. Abstract #LB7.
55. Nicholson K.G., Kent J., Ireland D.C. Respiratory viruses and exacerbations of asthma in adults. Br. Med. J. 307:1993;982-986.
56. Nicholson K.G., Kent J., Hammersley V., Cancio E. Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. Br. Med. J. 313:1996;1119-1123.
57. Nicholson K.G., Kent J., Hammersley V., Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. Br. Med. J. 315:1997;1060-1064.
58. Noah T.L., Becker S. Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. Am. J. Physiol. 265:1993;472-478.
59. Patriarca P.A., Arden N.H., Koplan J.P., Goodman R.A. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann. Int. Med. 107:1987;732-740.
60. Paxton L.A., Redd S.C., Steketee R.W., Otieno J.O., Nahlen B. An evaluation of clinical indicators for severe paediatric illness. Bull. WHO. 74:1996;613-618.
61. Pelletier D.L., Frongillo E.A. Jr., Schroeder D.G., Habicht J.P. The effects of malnutrition on child mortality in developing countries. Bull. WHO. 73:1995;443-448.
62. Pitkäranta A., Arruda E., Malmberg H., Hayden F.G. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J. Clin. Microbiol. 35:1997;1791-1793.
63. Pitkäranta A., Virolainen A., Jero J. Detection of rhinovirus respiratory syncytial virus and coronavirus infections in acute otitis media by reverse transcription-PCR. Pediatrics. 102:1998;291-295.
64. Pitkäranta A., Jero J., Arruda E., Virolainen A., Hayden F.G. Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. J. Pediatr. 133:1998;390-394.
65. Prince G.A., Horswood R.L., Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55:1985;517-520.
66. Puck J.M., Glezen W.P., Frank A.L., Six H.R. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J. Infect. Dis. 142:1980;844-849.
67. Renzi P.M., Turgeon J.P., Yang J.P., Drblik S.P., Marcotte J.E., Pedneault L., Spier S. Cellular immunity is activated and a TH-2 response is associated with early wheezing in infants after bronchiolitis. J. Pediatr. 130:1997;584-593.
68. Rodriguez W.J., Gruber W.C., Groothuis J.R., Simoes E.A., Rosas A.J., Lepow M., Kramer A., Hemming V. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 100:1997;937-942.
69. Ruutu P., Halonen P., Meurman O., Torres C., Paladin F., Yamaoka K., Tupasi T.E. Viral lower respiratory tract infections in Filipino children. J. Infect. Dis. 161:1990;175-179.
70. Sarawar S.R., Carding S.R., Allan W., McMickle A., Fujihashi K., Kiyono H., McGhee J.R., Doherty P.C. Cytokine profiles of bronchoalveolar lavage cells from mice with influenza pneumonia: consequences of CD4+ and CD8+ T cell depletion. Reg. Immunol. 5:1993;142-150.
71. Scherle P.A., Palladino G., Gerhard W. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J. Immunol. 148:1992;212-217.
72. Schilling M., Povinelli L., Krause P., Gravenstein M., Ambrozaitis A., Jones H.H., Drinka P., Shult P., Powers D., Gravenstein S. Efficacy of zanamivir of chemoprophylaxis of nursing home influenza A outbreaks. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997;American Society for Microbiology, Toronto. Abstract #H-92.
73. Selwyn B.J. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev. Infect. Dis. 12(Suppl. 8):1990;870-888.
74. Siber G.R., Leombruno D., Leszczynski J., McIver J., Bodkin D., Gonin R., Thompson C.M., Walsh E.E., Piedra P.A., Hemming V.G. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 169:1994;1368-1373.
75. Skiadopoulos M.H., Surman S., Tatem J.M., Paschalis M., Wu S.L., Udem S.A., Durbin A.P., Collins P.L., Murphy B.R. Identification of mutations contributing to the temperature sensitive, cold-adapted, and attenuation phenotypes of the live attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73:1999;1374-1381.
76. Smyth R.L., Fletcher J.N., Thomas H.M., Hart C.A. Immunological responses to respiratory syncytial virus infection in infancy. Arch. Dis. Child. 76:1997;210-214.
77. Stark J.M., Godding V., Sedgwick J.B., Busse W.W. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. J. Immunol. 156:1996;4774-4782.
78. Sutmoller F., Ferro Z.P., Asensi M.D., Ferreira V., Mazzei I.S., Cunha B.L. Etiology of acute respiratory tract infections among children in a combined community and hospital study in Rio de Janeiro. Clin. Infect. Dis. 20:1995;854-860.
79. Tao T., Durbin A.P., Whitehead, Davoodi F., Collins P.L., Murphy B.R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoprotein have been replaced by those of PIV type 1. J. Virol. 72:1998;2955-2961.
80. Taubenberger J.K., Reid A.H., Krafft A.E., Bijwaard K.E., Fanning T.G. Initial genetic characterization of the 1918 'Spanish' influenza virus. Science. 275:1997;1793-1796.
81. Teran L.M., Johnston S.L., Schroder J.M., Church M.K., Holgate S.T. Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am. J. Respir. Crit. Care Med. 155:1997;1362-1366.
82. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections. Lancet. 352:1998;1877-1881.
83. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537.
84. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 99:1997;93-99.
85. Topham D.J., Doherty P.C. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J. Virol. 72:1998;882-885.
86. Treanor J.J., Betts R.F., Smith G.E., Anderson E.L., Hackett C.S., Wilkinson B.E., Belshe R.B., Powers D.C. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 173:1996;1467-1470.
87. Treanor J.J., Vrooman P.S., Hayden F.G., Kinnersley P., Ward P., Mills R.G. Efficacy of oral GS4104 in treating acute influenza. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998;American Society of Microbiology, San Diego. Abstract #LB4.
88. Vital and Health Statistics from the Center for Disease Control and Prevention/National Center for Health Statistics, 1998. Current Estimates from the National Health Interview Survey 1995, Series 10, Na 199. US Department of Health and Human Services, Hyatsville MA, pp. 1-428.
89. Weber M.W., Dackour R., Usen S., Schneider G., Adegbola R.A., Cane P., Jaffar S., Milligan P., Greenwood B.M., Whittle H., Mulholland E.K. The clinical spectrum of respiratory syncytial virus disease in The Gambia. Pediatr. Infect. Dis. J. 17:1998;224-230.
90. White J.M. Membrane fusion. Science. 258:1992;917-924. (review).
91. Whitehead S.S., Firestone C.-Y., Collins P.L., Murphy B.R. A single nucleotide substitution in the transcription start of the M2 gene of respiratory syncitial virus candidate cpts 248/404 is the major determinant of the temperature sensitive and attenuation phenotypes. Virology. 247:1998;232-239.
92. Whitehead S.S., Firestone C.-Y., Karron R.A., Crowe J.E. Jr., Elkins W.R., Collins P.L., Murphy B.R. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts 530/1030 to RSV vaccine candidate cpts 248404 increases its attenuation and temperature sensitivity. J. Virol. 73:1999;871-877.
93. Wild C., Greenwell T., Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses. 9:1993;1051-1053. (letter).
94. Yao Q., Compans R.W. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology. 223:1996;103-112.